Bioxytran, Inc. (BIXT)

OTCMKTS · Delayed Price · Currency is USD
0.0778
-0.0002 (-0.21%)
Sep 8, 2025, 11:27 AM EDT
-0.21%
Market Cap6.84M
Revenue (ttm)n/a
Net Income (ttm)-2.46M
Shares Out88.99M
EPS (ttm)-0.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume43,000
Average Volume121,542
Open0.0760
Previous Close0.0780
Day's Range0.0730 - 0.0778
52-Week Range0.0606 - 0.2283
Beta1.95
RSI46.73
Earnings DateAug 14, 2025

About Bioxytran

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 3
Stock Exchange OTCMKTS
Ticker Symbol BIXT
Full Company Profile

Financial Performance

Financial Statements

News

Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation

BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a pioneering clinical stage biotechnology company at the forefront of oxygen therapeutics, is pr...

24 days ago - GlobeNewsWire

Bioxytran's Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection Treatment

- ProLectin-M is currently being developed under an active Investigational New Drug (IND) application with the FDA BOSTON, MASSACHUSETTS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT...

4 weeks ago - GlobeNewsWire

Bioxytran Secures a Source of GMP Quality Camel Hemoglobin

- First use of camel hemoglobin as a universal oxygen carrier - Unique properties make it an ideal ingredient for oxygen transport BOSTON, MASSACHUSETTS, June 18, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, I...

2 months ago - GlobeNewsWire

Bioxytran's Groundbreaking Stroke & Alzheimer's Tech Gains Validation That Measures Oxygenation Uptake During Strokes

Mongolian Gerbil Research Unlocks Critical Insights for Ischemic Stroke and Neurodegenerative Disease Treatments

3 months ago - GlobeNewsWire

Bioxytran's Antiviral Breakthrough Featured in University of Georgia's $100M HPAI Poultry Innovation Grand Challenge Submission

PHM23 was one of a handful of molecules chosen by the university Bird Flu helping PHM23 gain awareness of broad-spectrum activity at a university level BOSTON, MASSACHUSETTS, May 21, 2025 (GLOBE NEWSW...

3 months ago - GlobeNewsWire

Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M

BOSTON, MASSACHUSETTS, May 12, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel antiviral therapies, today announced the ...

4 months ago - GlobeNewsWire

Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements

- The universal oxygen carrier delivery capabilities of BXT-25 can be monitored, broadening its applications to treat hypoxic diseases

5 months ago - GlobeNewsWire

Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens

In Vitro studies have shown promise against viruses similar to the bird flu virus BOSTON, MASSACHUSETTS, March 19, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical st...

6 months ago - GlobeNewsWire

Bioxytran Develops a Groundbreaking Treatment to Combat Bird Flu in Egg Laying Chickens Potentially Saving Billions

New water-soluble galectin antagonist being considered in preclinical trials offering hope for rapid containment to H5N1 outbreaks

6 months ago - GlobeNewsWire

Bioxytran's Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs

BOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral dise...

8 months ago - GlobeNewsWire

Bioxytran's Medical Breakthrough in Fighting All Viruses

Breakthrough was validated in the latest journal article Galectins are essential for viral entry and a new target for drug development Carbohydrates were shown to neutralize viruses Blocking galectins...

1 year ago - Accesswire

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024.

1 year ago - GlobeNewsWire

Bioxytran Launches Joint Venture with the Heme Foundation for Development of Universal Oxygen Carrier

The Heme Foundation and Bioxytran join forces to address the global blood supply shortage BOSTON, MASSACHUSETTS, July 18, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clin...

1 year ago - GlobeNewsWire

Bioxytran's Advisor Releases Book on Hyperbaric Oxygenation Related to Stroke & Alzheimer's Patients

BXT-25 is expected to oxygenate the brain BOSTON, MASSACHUSETTS, June 27, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing drug...

1 year ago - GlobeNewsWire

Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist

50% Lesion clearance and regression of Herpes Zoster Neuralgia within 48 – 72 hours BOSTON, MASSACHUSETTS, March 06, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage ...

1 year ago - GlobeNewsWire

Bioxytran's Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19

First Medicinal chemistry of an antiviral drug made of sugars BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:  BIXT), (the “Company”), a clinical stage biotechnology ...

1 year ago - GlobeNewsWire

Bioxytran Gets Broad Patent Coverage on 60+ Viruses

Claims cover method of treating a viral infection with a lectin-binding carbohydrate BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage ...

2 years ago - GlobeNewsWire

Bioxytran Interview at the Emerging Growth Conference

BOSTON, MASSACHUSETTS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 a...

2 years ago - GlobeNewsWire

Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M

BOSTON, MASSACHUSETTS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseas...

2 years ago - GlobeNewsWire

Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials

BOSTON, MASSACHUSETTS, Aug. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral disease...

2 years ago - GlobeNewsWire

Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients

BOSTON, MASSACHUSETTS, Aug. 08, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral disease...

2 years ago - GlobeNewsWire

Bioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board

BOSTON, MASSACHUSETTS, July 31, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral disease...

2 years ago - GlobeNewsWire

Bioxytran Peer-Reviewed Journal in “Vaccines” Contains Mechanism Capable of Targeting Future COVID-19 Mutations

Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001) Complete elimination of most symptoms by day 7 Galectin antagonist acts as an entry inhibitor for use in treat...

2 years ago - GlobeNewsWire

Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment

- Funding in place to meet next regulatory milestone BOSTON, MASSACHUSETTS, June 12, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing...

2 years ago - GlobeNewsWire

Bioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials

BOSTON, MASSACHUSETTS, April 19, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseas...

2 years ago - GlobeNewsWire